These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 29293113)

  • 1. Low Doses of Etanercept Can Be Effective to Maintain Remission in Psoriatic Arthritis Patients.
    de Stefano R; Frati E; de Quattro D; de Stefano L
    J Clin Rheumatol; 2018 Apr; 24(3):127-131. PubMed ID: 29293113
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Maintenance of remission and monotherapy status over 66 months in patients with psoriatic arthritis receiving etanercept.
    de Vlam K; Bruhwyler J; Boone C;
    Clin Exp Rheumatol; 2016; 34(6):1094-1097. PubMed ID: 27606973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients.
    De Stefano R; Frati E; De Quattro D; Menza L; Manganelli S
    Clin Rheumatol; 2014 May; 33(5):707-11. PubMed ID: 24062201
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term etanercept survival in patients with psoriatic arthritis: a multicenter retrospective analysis in daily clinical practice in Spain.
    Deza G; Notario J; Ferran M; Beltrán E; Almirall M; Alcalá R; Ruiz-Carrascosa JC; Sánchez R; Pérez S; García-Vivar ML; Galíndez E; Mora M; Rodríguez J; Gallardo F
    Rheumatol Int; 2018 Nov; 38(11):2037-2043. PubMed ID: 30143818
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Effect of Reduced or Withdrawn Etanercept-methotrexate Therapy on Patient-reported Outcomes in Patients with Early Rheumatoid Arthritis.
    Wiland P; Dudler J; Veale D; Tahir H; Pedersen R; Bukowski J; Vlahos B; Williams T; Gaylord S; Kotak S
    J Rheumatol; 2016 Jul; 43(7):1268-77. PubMed ID: 27252426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical and economic impact of the use of etanercept 25 mg once weekly in rheumatoid arthritis, psoriatic arthropathy and ankylosing spondylitis patients.
    Borrás-Blasco J; Gracia-Pérez A; Rosique-Robles JD; Casterá ME; Abad FJ
    Expert Opin Biol Ther; 2014 Feb; 14(2):145-50. PubMed ID: 24359492
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity-results from the ENCOURAGE study, a prospective, international, multicenter randomized study.
    Yamanaka H; Nagaoka S; Lee SK; Bae SC; Kasama T; Kobayashi H; Nishioka Y; Ueki Y; Seto Y; Nishinarita M; Tamura N; Kimura N; Saito K; Tomita T; Nawata Y; Suzuki S; Ishigatsubo Y; Munakata Y; Makino Y; Inoue E; Tanaka Y; Takeuchi T;
    Mod Rheumatol; 2016 Sep; 26(5):651-61. PubMed ID: 26698929
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Two-year Efficacy and Safety of Etanercept in Pediatric Patients with Extended Oligoarthritis, Enthesitis-related Arthritis, or Psoriatic Arthritis.
    Constantin T; Foeldvari I; Vojinovic J; Horneff G; Burgos-Vargas R; Nikishina I; Akikusa JD; Avcin T; Chaitow J; Koskova E; Lauwerys BR; Calvo Penades I; Flato B; Gamir ML; Huppertz HI; Jaller Raad JJ; Jarosova K; Anton J; Macku M; Otero Escalante WJ; Rutkowska-Sak L; Trauzeddel R; Velez-Sanchez PJ; Wouters C; Wajdula J; Zang C; Bukowski J; Woodworth D; Vlahos B; Martini A; Ruperto N;
    J Rheumatol; 2016 Apr; 43(4):816-24. PubMed ID: 26932344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two etanercept regimens for treatment of psoriasis and psoriatic arthritis: PRESTA randomised double blind multicentre trial.
    Sterry W; Ortonne JP; Kirkham B; Brocq O; Robertson D; Pedersen RD; Estojak J; Molta CT; Freundlich B
    BMJ; 2010 Feb; 340():c147. PubMed ID: 20124563
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.
    Pavelka K; Akkoç N; Al-Maini M; Zerbini CAF; Karateev DE; Nasonov EL; Rahman MU; Pedersen R; Dinh A; Shen Q; Vasilescu R; Kotak S; Mahgoub E; Vlahos B
    Rheumatol Int; 2017 Sep; 37(9):1469-1479. PubMed ID: 28597306
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis.
    van Vollenhoven RF; Østergaard M; Leirisalo-Repo M; Uhlig T; Jansson M; Larsson E; Brock F; Franck-Larsson K
    Ann Rheum Dis; 2016 Jan; 75(1):52-8. PubMed ID: 25873634
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of half dose etanercept (25 mg once a week) on clinical remission and radiographic progression in patients with rheumatoid arthritis in clinical remission achieved with standard dose.
    Raffeiner B; Botsios C; Ometto F; Bernardi L; Stramare R; Todesco S; Sfriso P; Punzi L
    Clin Exp Rheumatol; 2015; 33(1):63-8. PubMed ID: 25535985
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early treatment of psoriatic arthritis is associated with improved patient-reported outcomes: findings from the etanercept PRESTA trial.
    Kirkham B; de Vlam K; Li W; Boggs R; Mallbris L; Nab HW; Tarallo M
    Clin Exp Rheumatol; 2015; 33(1):11-9. PubMed ID: 25535650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study.
    Perrotta FM; Lubrano E
    Postgrad Med; 2016 Sep; 128(7):693-6. PubMed ID: 27494077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The use of adalimumab, etanercept, golimumab and infliximab in rheumatic pathologies: variation between label dosage and real-world use.
    Martinez-Cutillas J; Alerany-Pardo C; Borrás-Blasco J; Broto-Sumalla A; Burgos-SanJosé A; Climent-Bolta C; Escudero-Vilaplana V; Fernández-Fuente MA; Ferrit-Martin M; Gómez-Germá P; Martínez-Sesmero JM; Mayorga-Pérez J; Menchén-Viso B; Merino-Alonso J; Polache-Vengud J; Sánchez-Guerrero A
    Expert Rev Pharmacoecon Outcomes Res; 2015; 15(5):851-8. PubMed ID: 25972066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption.
    Laganà B; Picchianti Diamanti A; Ferlito C; Germano V; Migliore A; Cremona A; Argento G; David V; Salemi S; D'Amelio R
    Int J Immunopathol Pharmacol; 2009; 22(2):447-54. PubMed ID: 19505397
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of etanercept in psoriasis and psoriatic arthritis in the PRESTA study: analysis in patients from Central and Eastern Europe.
    Damjanov N; Karpati S; Kemeny L; Bakos N; Bobic B; Majdan M; Tlustochowicz W; Vitek P; Dokoupilova E; Aldinc E; Szumski A
    J Dermatolog Treat; 2018 Feb; 29(1):8-12. PubMed ID: 28506134
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of remission with etanercept-methotrexate induction therapy and loss of remission with etanercept maintenance, reduction, or withdrawal in moderately active rheumatoid arthritis: results of the PRESERVE trial.
    Smolen JS; Szumski A; Koenig AS; Jones TV; Marshall L
    Arthritis Res Ther; 2018 Jan; 20(1):8. PubMed ID: 29338762
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remission of psoriatic arthritis after etanercept discontinuation: analysis of patients' clinical characteristics leading to disease relapse.
    Chimenti MS; Esposito M; Giunta A; Graceffa D; Babino G; Teoli M; Mazzotta A; Pericone R; Chimenti S
    Int J Immunopathol Pharmacol; 2013; 26(3):833-8. PubMed ID: 24067486
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of Etanercept Monotherapy and Combination Therapy with Methotrexate in Psoriatic Arthritis: Results from 2 Clinical Trials.
    Combe B; Behrens F; McHugh N; Brock F; Kerkmann U; Kola B; Gallo G
    J Rheumatol; 2016 Jun; 43(6):1063-7. PubMed ID: 27134249
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.